Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection

Hideo Yoshida; Tomoaki Kato; David M. Levi; Arie Regev; Juan R. Madariaga; Seigo Nishida; Enrique J. Martinez; Eugene R. Schiff; Masao Omata; Andreas G. Tzakis

doi:10.1111/j.1399-0012.2006.00557.x

Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection

Hideo Yoshida, Tomoaki Kato, David M. Levi, Arie Regev, Juan R. Madariaga, Seigo Nishida, Enrique J. Martinez, Eugene R. Schiff, Masao Omata, Andreas G. Tzakis

Research output: Contribution to journal › Article

39 Scopus citations

Abstract

Background: The aim of this study was to evaluate the efficacy of lamivudine (LAM) monoprophylaxis for patients with non-replicating hepatitis B virus (HBV) infection at orthotopic liver transplantation (OLT). Methods: Among 128 liver recipients with HBV infection between 1994 and 2004 transplanted at our institution, 60 had non-replicating HBV infection at the time of OLT. Of those, 26 patients received LAM prophylaxis (monoprophylaxis group) and 34 patients received LAM and hepatitis B immunoglobulin (HBIG) prophylaxis (combination group) after OLT. Results: Median follow-up after OLT was 67 and 54 months, for monoprophylaxis and combination groups respectively. One and five yr patient/graft survival were 96/85% and 96/80% in monoprophylaxis group, and 85/79% and 67/55% in combination group. HBV DNA was re-detected or increased >10 ⁵ IU/mL in four patients (15%) at 20-29 month in monoprophylaxis group and six (18%) at 4-35 months in combination group. Recurrent hepatitis was seen in two patients (8%) at 27 and 45 months and monoprophylaxis group and three (9%) at 21-35 months in combination group. The rate of recurrence was not statistically different between two groups. Conclusion: LAM monoprophylaxis seemed to be effective for OLT recipients with HBV infection who had non-replicating HBV at transplantation. HBIG administration may play a less valuable role in preventing HBV recurrence in this group of patients.

Original language	English (US)
Pages (from-to)	166-171
Number of pages	6
Journal	Clinical Transplantation
Volume	21
Issue number	2
DOIs	https://doi.org/10.1111/j.1399-0012.2006.00557.x
State	Published - Mar 2007

Keywords

Hepatitis B immunoglobulin
Hepatitis B virus
Lamivudine
Liver transplantation

ASJC Scopus subject areas

Transplantation
Immunology

Access to Document

10.1111/j.1399-0012.2006.00557.x

Fingerprint Dive into the research topics of 'Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection'. Together they form a unique fingerprint.

Cite this

Yoshida, H., Kato, T., Levi, D. M., Regev, A., Madariaga, J. R., Nishida, S., Martinez, E. J., Schiff, E. R., Omata, M., & Tzakis, A. G. (2007). Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clinical Transplantation, 21(2), 166-171. https://doi.org/10.1111/j.1399-0012.2006.00557.x

Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. / Yoshida, Hideo; Kato, Tomoaki; Levi, David M.; Regev, Arie; Madariaga, Juan R.; Nishida, Seigo; Martinez, Enrique J.; Schiff, Eugene R.; Omata, Masao; Tzakis, Andreas G.

In: Clinical Transplantation, Vol. 21, No. 2, 03.2007, p. 166-171.

Research output: Contribution to journal › Article

@article{04526fdea5e84254ae96a89f4cd12762,

title = "Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection",

abstract = "Background: The aim of this study was to evaluate the efficacy of lamivudine (LAM) monoprophylaxis for patients with non-replicating hepatitis B virus (HBV) infection at orthotopic liver transplantation (OLT). Methods: Among 128 liver recipients with HBV infection between 1994 and 2004 transplanted at our institution, 60 had non-replicating HBV infection at the time of OLT. Of those, 26 patients received LAM prophylaxis (monoprophylaxis group) and 34 patients received LAM and hepatitis B immunoglobulin (HBIG) prophylaxis (combination group) after OLT. Results: Median follow-up after OLT was 67 and 54 months, for monoprophylaxis and combination groups respectively. One and five yr patient/graft survival were 96/85% and 96/80% in monoprophylaxis group, and 85/79% and 67/55% in combination group. HBV DNA was re-detected or increased >10 5 IU/mL in four patients (15%) at 20-29 month in monoprophylaxis group and six (18%) at 4-35 months in combination group. Recurrent hepatitis was seen in two patients (8%) at 27 and 45 months and monoprophylaxis group and three (9%) at 21-35 months in combination group. The rate of recurrence was not statistically different between two groups. Conclusion: LAM monoprophylaxis seemed to be effective for OLT recipients with HBV infection who had non-replicating HBV at transplantation. HBIG administration may play a less valuable role in preventing HBV recurrence in this group of patients.",

keywords = "Hepatitis B immunoglobulin, Hepatitis B virus, Lamivudine, Liver transplantation",

author = "Hideo Yoshida and Tomoaki Kato and Levi, {David M.} and Arie Regev and Madariaga, {Juan R.} and Seigo Nishida and Martinez, {Enrique J.} and Schiff, {Eugene R.} and Masao Omata and Tzakis, {Andreas G.}",

year = "2007",

month = mar,

doi = "10.1111/j.1399-0012.2006.00557.x",

language = "English (US)",

volume = "21",

pages = "166--171",

journal = "Clinical Transplantation",

issn = "0902-0063",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection

AU - Yoshida, Hideo

AU - Kato, Tomoaki

AU - Levi, David M.

AU - Regev, Arie

AU - Madariaga, Juan R.

AU - Nishida, Seigo

AU - Martinez, Enrique J.

AU - Schiff, Eugene R.

AU - Omata, Masao

AU - Tzakis, Andreas G.

PY - 2007/3

Y1 - 2007/3

N2 - Background: The aim of this study was to evaluate the efficacy of lamivudine (LAM) monoprophylaxis for patients with non-replicating hepatitis B virus (HBV) infection at orthotopic liver transplantation (OLT). Methods: Among 128 liver recipients with HBV infection between 1994 and 2004 transplanted at our institution, 60 had non-replicating HBV infection at the time of OLT. Of those, 26 patients received LAM prophylaxis (monoprophylaxis group) and 34 patients received LAM and hepatitis B immunoglobulin (HBIG) prophylaxis (combination group) after OLT. Results: Median follow-up after OLT was 67 and 54 months, for monoprophylaxis and combination groups respectively. One and five yr patient/graft survival were 96/85% and 96/80% in monoprophylaxis group, and 85/79% and 67/55% in combination group. HBV DNA was re-detected or increased >10 5 IU/mL in four patients (15%) at 20-29 month in monoprophylaxis group and six (18%) at 4-35 months in combination group. Recurrent hepatitis was seen in two patients (8%) at 27 and 45 months and monoprophylaxis group and three (9%) at 21-35 months in combination group. The rate of recurrence was not statistically different between two groups. Conclusion: LAM monoprophylaxis seemed to be effective for OLT recipients with HBV infection who had non-replicating HBV at transplantation. HBIG administration may play a less valuable role in preventing HBV recurrence in this group of patients.

AB - Background: The aim of this study was to evaluate the efficacy of lamivudine (LAM) monoprophylaxis for patients with non-replicating hepatitis B virus (HBV) infection at orthotopic liver transplantation (OLT). Methods: Among 128 liver recipients with HBV infection between 1994 and 2004 transplanted at our institution, 60 had non-replicating HBV infection at the time of OLT. Of those, 26 patients received LAM prophylaxis (monoprophylaxis group) and 34 patients received LAM and hepatitis B immunoglobulin (HBIG) prophylaxis (combination group) after OLT. Results: Median follow-up after OLT was 67 and 54 months, for monoprophylaxis and combination groups respectively. One and five yr patient/graft survival were 96/85% and 96/80% in monoprophylaxis group, and 85/79% and 67/55% in combination group. HBV DNA was re-detected or increased >10 5 IU/mL in four patients (15%) at 20-29 month in monoprophylaxis group and six (18%) at 4-35 months in combination group. Recurrent hepatitis was seen in two patients (8%) at 27 and 45 months and monoprophylaxis group and three (9%) at 21-35 months in combination group. The rate of recurrence was not statistically different between two groups. Conclusion: LAM monoprophylaxis seemed to be effective for OLT recipients with HBV infection who had non-replicating HBV at transplantation. HBIG administration may play a less valuable role in preventing HBV recurrence in this group of patients.

KW - Hepatitis B immunoglobulin

KW - Hepatitis B virus

KW - Lamivudine

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=33947722589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947722589&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2006.00557.x

DO - 10.1111/j.1399-0012.2006.00557.x

M3 - Article

C2 - 17425740

AN - SCOPUS:33947722589

VL - 21

SP - 166

EP - 171

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -